Bifogade filer
LIPUM Kvartalsrapport Juli September 2022
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Lipum via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2022-11-25 08:30:00
Lipum AB has published the interim report for period July-September 2022. Below is a short summary, a complete report (only in Swedish) is available on the company's website.
CEO Einar Pontén comments: “In early November, we were able to report that our Phase 1 clinical trial had started. Preparations for this were a major activity of the third quarter. I am very pleased and grateful for the excellent efforts made by our staff to bring us to this milestone. At the same time, it is with excitement that I note that there is now more going on at Lipum than ever before.”
Financial summary January - September 2022
- Net sales: KSEK 0 (0)
- Result after financial items: -25 068 KSEK (-23 080)
- Cash and cash equivalents as of September 30: 9 482 KSEK (61 941)
Significant events during July to September 2022
- Clinical trial application of drug candidate SOL-116 approved by the Dutch Medicines Agency and Ethics Committee.
- The Board decided on a directed share issue at a price of SEK 14.99 per share.
Significant events after the period
- An Extraordinary General Meeting approved the Board's proposal for a directed share issue and the company was injected with SEK 39 million before transaction costs of SEK 0.9 million.
- Phase 1 clinical trial with drug candidate SOL-116 started at the company's partner QPS Netherlands B.V. site in the Netherlands.
Link to the full report (in Swedish): Interim report